Overview GLP3-R is the catalog designation for retatrutide (LY3437943), a synthetic peptide characterized in the peer-reviewed literature as a single-molecule agonist at three receptors: GIP, GLP-1, and glucagon.[1] Coskun and colleagues published the discovery-to-proof-of-concept characterization in Cell Metabolism, and Urva et al. reported the first multiple-ascending-dose clinical pharmacology study in The Lancet.[1][2] What distinguishes this compound within the incretin literature is the th

How does GLP3-R work? What is its mechanism of action?

Reported Mechanism 1. Triple Receptor Engagement Retatrutide is described as engaging three class-B G-protein-coupled receptors with a single peptide sequence: the GIP receptor, the GLP-1 receptor, and the glucagon receptor.[1] This distinguishes it from dual GIP/GLP-1 agonism and from GLP-1-selective agonism, and it is the structural feature that defines the compound's research role.[8] 2. Incretin-Axis Signalling GLP-1 and GIP receptor agonism act on the incretin axis, where insulinotropic act

What are the research applications of GLP3-R?

Research Applications Published investigations of retatrutide fall into the following areas. All studies listed used the pharmaceutical formulation. Receptor pharmacology and discovery characterization — Coskun et al. reported the discovery-to-proof-of-concept work defining triple GIP/GLP-1/glucagon agonism.[1] Clinical pharmacology and dose-ranging — Urva et al. published a phase 1b multiple-ascending-dose trial in people with type 2 diabetes.[2] Obesity research — Jastreboff et al. reported a

What does the research summary say about GLP3-R?

Research Summary Foundational Studies StudyTypeSubject of ReportRef Coskun et al. (2022)Discovery / proof of conceptCharacterization of LY3437943 as a triple glucagon, GIP, and GLP-1 receptor agonist[1] Urva et al. (2022)Phase 1b multiple-ascending doseClinical pharmacology in people with type 2 diabetes[2] Jastreboff et al. (2023)Phase 2 (obesity)Triple-hormone-receptor agonist evaluated in adults with obesity[3] Rosenstock et al. (2023)Phase 2 (type 2 diabetes)Placebo- and active-controlled pa

How should GLP3-R be stored?

Store lyophilized at -20°C for long-term storage, or 2-8°C short-term. After reconstitution with bacteriostatic water, store refrigerated (2-8°C) and avoid repeated freeze-thaw cycles.

GLP3-R: Safety Profile & Research Summary

10 Citacoes PubMedRevisado por EspecialistasCertificado GMPUltima Revisao: julho de 2026

Research Summary

Foundational Studies

Study	Type	Subject of Report	Ref
Coskun et al. (2022)	Discovery / proof of concept	Characterization of LY3437943 as a triple glucagon, GIP, and GLP-1 receptor agonist	[1]
Urva et al. (2022)	Phase 1b multiple-ascending dose	Clinical pharmacology in people with type 2 diabetes	[2]
Jastreboff et al. (2023)	Phase 2 (obesity)	Triple-hormone-receptor agonist evaluated in adults with obesity	[3]
Rosenstock et al. (2023)	Phase 2 (type 2 diabetes)	Placebo- and active-controlled parallel-group trial	[4]
Sanyal et al. (2024)	Phase 2a (MASLD)	Randomized trial in metabolic dysfunction-associated steatotic liver disease	[5]
Urva et al. (2023)	Pharmacodynamics	Reported delay in gastric emptying	[6]

Mechanistic Themes

Triple receptor agonism - one peptide engages the GIP, GLP-1, and glucagon receptors
Graded comparator series - selective, dual, and triple agonists allow receptor contributions to be separated
Glucose-dependent incretin action - insulinotropic activity in this class is conditioned on ambient glucose
Investigational status - no regulatory approval in any jurisdiction

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

In Vitro / Preclinical Disclaimer: The research findings described above were observed in laboratory (in vitro), animal model, and clinical research studies of the pharmaceutical product. Research-grade material sold here is for laboratory research use only. No claims are made regarding human therapeutic applications.

Educational Use Only: This content is provided for informational and educational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult qualified healthcare professionals for medical decisions.

Editorial Research Note

“Research Summary Foundational Studies StudyTypeSubject of ReportRef Coskun et al.”

Pure U.S. Peptides Research Standards TeamInternal editorial group summarising published peptide research for an audience of qualified independent investigators.

Referencias

Perguntas de Pesquisa Relacionadas

→ What Is GLP3-R?→ GLP3-R: Mechanism of Action → GLP3-R: Research Applications → GLP3-R: Chemical Properties → Storing GLP3-R: Best Practices

Related research

What is Semaglutide?What is Tirzepatide?What is Cagriniltide?

Browse all research guides in the Peptide Research Library →

Deseja a revisao completa da pesquisa?

Ver Pagina Completa de Pesquisa de GLP3-R→

APENAS PARA USO EM PESQUISA

Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.